Results 41 to 50 of about 14,308 (181)

Uso tópico do inteferon alfa-2b para neoplasia escamosa da superficie ocular em um caso de paciente com xeroderma pigmentoso

Revista Brasileira de Oftalmologia
Resumo Relato de um caso clínico de Xeroderma Pigmentoso com carcinoma espinocelular de conjuntiva bilateral que apresentou regressão importante das dimensões tumorais com o uso de Interferon alfa-2b tópico.
Nayara Queiroz Cardoso Pinto, Jhonatan de Paula Araujo Ferreira, Gustavo Jose Arruda Mendes Carneiro, Jailton Vieira Silva, Luanna Biana Costa Bezerra, Natália Ponte Nogueira   +5 more
doaj   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy

Journal of Translational Medicine, 2006
Background Oxidative stress could play a role in pathogenesis of hepatitis C virus (HCV) infection. The aim of our study is to determine oxidant/antioxidant status of patients with chronic hepatitis C (CHC), and the effect of pegylated interferon alfa-2b
Aytaç Çetinkaya, Polat Eyigun, Ahmet Aydın, Ali Acar, Levent Görenek, Ayşe Eken, Ahmet Sayal   +6 more
doaj   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Jet Injections With Candida Antigen for Wart Treatment: An Alternative Drug Delivery

Pediatric Dermatology, EarlyView.
ABSTRACT Warts are a common pediatric condition caused by human papillomavirus. Immunotherapy is a well‐studied treatment for warts and is classically administered via intralesional injection with a syringe and needle. We report a case of warts in a 12‐year‐old boy who achieved complete resolution following two sessions of pain‐free, and needleless ...
Mary Nan Leath, Theodore Katz, Kimberly Eisenstein   +2 more
wiley   +1 more source

Role of RIPK1/RIPK3/MLKL signalling pathway in sepsis‐associated acute kidney injury

Experimental Physiology, EarlyView.
Abstract Sepsis‐associated acute kidney injury (SA‐AKI) is a common clinical syndrome in critically ill patients, and its high mortality rate is closely related to complex pathological mechanisms. Existing studies have shown that the pathophysiological process of SA‐AKI involves complex multi‐mechanism interactions, including an uncontrolled systemic ...
Huijun Yin, Jingyi Wang, Huirong Han
wiley   +1 more source

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4

Annals of Hepatology, 2013
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have
Juan José Urquijo, Moisés Diago, M.D., Jaume Boadas, Ramón Planas, Ricard Solá, Juan Angel del Olmo, Javier Crespo, José Carlos Erdozaín, María Dolores Antón, Carlos Arocena, Dolores Suarez, Josep Giné, Josep M Barrera, Javier Gracia-Samaniego, Ricardo Perez, Blai Dalmau, Miguel Montoro   +16 more
doaj   +1 more source

Systemic Interferon Alfa in Multiple Sclerosis

Archives of Neurology, 1989
To the Editor. —We wish to comment on the conclusions reached by Panitch 1 in his follow-up study of patients treated with subcutaneous interferon alfa. Panitch notes that patients treated with interferon alfa experienced a reduction in attack frequency from 1.33 per year to 0.47 per year over a mean follow-up of four years.
Weinshenker, BG, Ebers, G
openaire   +2 more sources

Nanoparticle‐Mediated Therapy for Glioma: Advances and Prospects

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Various nanocarriers, including liposomes, dendrimers, exosomes and gold nanoparticles, are designed to penetrate the blood‐brain barrier and deliver chemotherapy, radiotherapy, immunotherapy, gene therapy, phototherapy, magnetic hyperthermia and sonodynamic therapy for glioma.
Wenqian Jiang, Jing Fei, Rangrang Fan, Haifeng Chen, Liangxue Zhou, Gang Guo   +5 more
wiley   +1 more source

Interferon Tiloron Inductor Usage in Complex Therapy at Patients with Community-Acquired Pneumonia [PDF]

Саратовский научно-медицинский журнал, 2009
The article presents the research findings concerning the importance of changes of the contents in blood serum of interferon gamma (INF-γ), interferon alfa (INF-α), the tumor necrosis factor alfa (TNF-α), interleukin 4 (IL-4), interleukin8 (IL-8) and ...
N.B. Zakharova, G.N. Shemetova, O.A. Kiseleva   +2 more
doaj